BridgeBio Oncology Therapeutics (BBOT) investor relations material

Industry trends and macro environment

• China is accelerating drug development speed, making competition on speed challenging, but innovation remains a key differentiator for global players.

• AI is being integrated into workflows, improving hypothesis testing, cost reduction, and cycle times across research and business operations.

• FDA interactions are the most critical policy variable, especially for oncology programs targeting high unmet needs.

Pipeline updates and strategic priorities

• Strategic reprioritization focuses on high-priority indications with clear registration paths and significant patient benefit.

• BBO-8520, a G12C off/on inhibitor, is shifting focus from first-line to second-line settings, targeting patients previously treated with G12C inhibitors.

• BBO-8520 shows favorable response rates and safety profile, especially in combination with pembrolizumab, with no Grade 3 liver toxicity observed.

• Next data update for the G12C program is expected mid-2027, focusing on duration and signal confirmation in refractory populations.

Upcoming catalysts and data readouts

• Monotherapy data for pan-KRAS inhibitor BBO-11818 and breaker BBO-10203 expected in Q4, with broader combination data in mid-2027.

• BBO-11818 aims to demonstrate efficacy and differentiated safety in pancreatic cancer, with low skin toxicity and no stomatitis.

• BBO-10203 targets PI3Kα to block RAS-driven AKT pathway activation, with escalation data update expected in Q4.

• Combination strategies will initially focus on CRC and PDAC, with potential expansion guided by emerging data.